Genomed
Sequencing & gene therapy · Genetic disease, oncology
Overview
DNA-sequencing and genetic-diagnostics provider expanding into in-house gene-therapy (AAV) development for rare diseases.
What they do
Genomed S.A. is a Warsaw-based genomics company providing DNA sequencing and genetic diagnostics, including next-generation sequencing (NGS) panels, exome and whole-genome analysis, and bioinformatics for hospitals, researchers and patients. The company is listed on the Warsaw Stock Exchange's NewConnect market and files periodic reports through the EBI system. Alongside its established diagnostics services, Genomed has positioned itself under the banner of moving from "sequencing today, gene therapy tomorrow."
Lead program & status
Genomed's diagnostics business is its commercial core, while its R&D ambition is in-house gene-therapy development using AAV (adeno-associated virus) vectors for rare genetic diseases. Public materials and its annual report for 2023 (filed 2024) describe the company's intent to develop genetic therapies, with rare neurological and ophthalmic indications among the areas of interest. As of 2024 this gene-therapy work is at an early, pre-clinical research stage rather than in registered clinical trials, and Genomed has emphasized building the underlying vector and manufacturing know-how.
Why it matters
Combining clinical-grade sequencing with vector development is a vertically integrated bet: the same NGS capabilities that identify rare-disease mutations can feed candidate selection for AAV therapies, a niche where Polish in-house gene-therapy programs remain scarce.
FAQ
- What does Genomed do?
- Genomed provides DNA sequencing and genetic-diagnostics services (including NGS panels, exome and genome analysis) and is developing in-house AAV gene-therapy programs for rare diseases.
- Is Genomed publicly traded?
- Yes, Genomed S.A. is listed on the NewConnect market of the Warsaw Stock Exchange.
- How advanced is Genomed's gene-therapy work?
- As of 2024 the AAV gene-therapy effort is at an early R&D stage focused on building vector and manufacturing capabilities, not yet in registered clinical trials.
Technology
Genomed works in AAV Gene Therapy — Using a hollowed-out virus to deliver a working gene.
Read the AAV Gene Therapy brief →Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.